Tropism-modification strategies for targeted gene delivery using adenoviral vectors

Viruses

Volumn 2, Issue 10, 2010, Pages 2290-2355

  Coughlan, Lynda ^a   Alba, Raul ^a   Parker, Alan L ^a   Bradshaw, Angela C ^a   McNeish, Iain A ^b   Nicklin, Stuart A ^a   Baker, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adenovirus; Capsid protein; Detargeting; Ligand; Retargeting; Tropism

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; BLOOD CLOTTING FACTOR 10; CAPSID PROTEIN; DELTA 4 ARGINYLGLYCYLASPARTIC ACID; GROWTH FACTOR; MONOCLONAL ANTIBODY; PROTEOHEPARAN SULFATE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ADENOVIRUS 5; CARDIOVASCULAR SYSTEM; CHEMICAL MODIFICATION; CROSS LINKING; DNA MODIFICATION; GENETIC TRANSDUCTION; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE RESPONSE; LIVER CELL; LIVER TOXICITY; NONHUMAN; OVARY CANCER; PSEUDOTYPING; RECEPTOR BINDING; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS DETARGETING; VIRUS ENTRY; VIRUS RETARGETING;

ADENOVIRIDAE; MIRIDAE;

EID: 79952207509     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2102290     Document Type: Review

References (389)

1. Crawford-Miksza, L.; Schnurr, D.P. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J. Virol. 1996, 70, 1836-1844.
2. Seto, J.; Walsh, M.P.; Mahadevan, P.; Purkayastha, A.; Clark, J.M.; Tibbetts, C.; Seto, D. Genomic and bioinformatics analyses of HAdV-14p, reference strain of a re-emerging respiratory pathogen and analysis of B1/B2. Virus Res. 2009, 143, 94-105.
3. Martin, M.A.K.; Knipe, D.M.; Fields, B.N.; Howley, P.M.; Griffin, D; Lamb, R. Adenoviridae: The Viruses and Their Replication. In Fields' Virology, 5th ed.; Knipe, D.M., Ed.; Lippincott Williams and Wilkins Publishers: Philadelphia, USA, 2007; Volume 2, pp. 2355-2395.
4. Virus Taxonomy, VIIIth Report of the ICTV; Fauquet, C.M., Mayo, M.A., Maniloff, J., Desselberger, U., Ball, L.A., Eds.; Elsevier/Academic Press Publishers: London, UK, 2005.
5. Green, M.; Mackey, J.K.; Wold, W.S.; Rigden, P. Thirty-one human adenovirus serotypes (Ad1-Ad31) form five groups (A-E) based upon DNA genome homologies. Virology 1979, 93, 481-492.
6. Rosen, L. A hemagglutination-inhibition technique for typing adenoviruses. Am. J. Hyg. 1960, 71, 120-128.
7. Wadell, G. Molecular epidemiology of human adenoviruses. Curr. Top. Microbiol. Immunol. 1984, 110, 191-220.
8. Wadell, G.; Hammarskjold, M.L.; Winberg, G.; Varsanyi, T.M.; Sundell, G. Genetic variability of adenoviruses. Ann. N. Y. Acad. Sci. 1980, 354, 16-42.
9. Walsh, M.P.; Chintakuntlawar, A.; Robinson, C.M.; Madisch, I.; Harrach, B.; Hudson, N.R.; Schnurr, D.; Heim, A.; Chodosh, J.; Seto, D.; Jones, M.S. Evidence of molecular evolution driven by recombination events influencing tropism in a novel human adenovirus that causes epidemic keratoconjunctivitis. PLoS One 2009, 4, e5635.
10. Kaneko, H.; Suzutani, T.; Aoki, K.; Kitaichi, N.; Ishida, S.; Ishiko, H.; Ohashi, T.; Okamoto, S.; Nakagawa, H.; Hinokuma, R.; Asato, Y.; Oniki, S.; Hashimoto, T.; Iida, T.; Ohno, S. Epidemiological and virological features of epidemic keratoconjunctivitis due to new human adenovirus type 54 in Japan. Br. J. Ophthalmol. 2010, doi:10.1136/bjo.2009.178772.
11. Walsh, M.P.; Seto, J.; Jones, M.S.; Chodosh, J.; Xu, W.; Seto, D. Computational analysis identifies human adenovirus type 55 as a re-emergent acute respiratory disease pathogen. J. Clin. Microbiol. 2010, 48, 991-993.
12. Christensen, J.B.; Byrd, S.A.; Walker, A.K.; Strahler, J.R.; Andrews, P.C.; Imperiale, M.J. Presence of the adenovirus IVa2 protein at a single vertex of the mature virion. J. Virol. 2008, 82, 9086-9093.
13. Russell, W.C. Adenoviruses: update on structure and function. J. Gen. Virol. 2009, 90, 1-20.
14. Hasson, T.B.; Ornelles, D.A.; Shenk, T. Adenovirus L1 52- and 55-kilodalton proteins are present within assembling virions and colocalize with nuclear structures distinct from replication centers. J. Virol. 1992, 66, 6133-6142.
15. Hasson, T.B.; Soloway, P.D.; Ornelles, D.A.; Doerfler, W.; Shenk, T. Adenovirus L1 52- and 55-kilodalton proteins are required for assembly of virions. J. Virol. 1989, 63, 3612-3621.
16. Silvestry, M.; Lindert, S.; Smith, J.G.; Maier, O.; Wiethoff, C.M.; Nemerow, G.R.; Stewart, P.L. Cryo-electron microscopy structure of adenovirus type 2 temperature-sensitive mutant 1 reveals insight into the cell entry defect. J. Virol. 2009, 83, 7375-7383.
17. Rekosh, D.M.; Russell, W.C.; Bellet, A.J.; Robinson, A.J. Identification of a protein linked to the ends of adenovirus DNA. Cell 1977, 11, 283-295.
18. Robinson, A.J.; Younghusband, H.B.; Bellett, A.J. A circula DNA-protein complex from adenoviruses. Virology 1973, 56, 54-69.
19. Everitt, E.; Lutter, L.; Philipson, L. Structural proteins of adenoviruses. XII. Location and neighbor relationship among proteins of adenovirion type 2 as revealed by enzymatic iodination, immunoprecipitation and chemical cross-linking. Virology 1975, 67, 197-208.
20. Everitt, E.; Sundquist, B.; Pettersson, U.; Philipson, L. Structural proteins of adenoviruses. X. Isolation and topography of low molecular weight antigens from the virion of adenovirus type 2. Virology 1973, 52, 130-147.
21. Chroboczek, J.; Ruigrok, R.W.; Cusack, S. Adenovirus fiber. Curr. Top. Microbiol. Immunol. 1995, 199 (Pt 1), 163-200.
22. Green, N.M.; Wrigley, N.G.; Russell, W.C.; Martin, S.R.; McLachlan, A.D. Evidence for a repeating cross-beta sheet structure in the adenovirus fibre. EMBO J. 1983, 2, 1357-1365.
23. van Raaij, M.J.; Mitraki, A.; Lavigne, G.; Cusack, S. A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein. Nature 1999, 401, 935-938.
24. Mautner, V.; Pereira, H.G. Crystallization of a second adenovirus protein (the fibre). Nature 1971, 230, 456-457.
25. van Oostrum, J.; Burnett, R.M. Molecular composition of the adenovirus type 2 virion. J. Virol. 1985, 56, 439-448.
26. Bergelson, J.M.; Cunningham, J.A.; Droguett, G.; Kurt-Jones, E.A.; Krithivas, A.; Hong, J.S.; Horwitz, M.S.; Crowell, R.L.; Finberg, R.W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275, 1320-1323.
27. Bergelson, J.M.; Krithivas, A.; Celi, L.; Droguett, G.; Horwitz, M.S.; Wickham, T.; Crowell, R.L.; Finberg, R.W. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J. Virol. 1998, 72, 415-419.
28. Kirby, I.; Davison, E.; Beavil, A.J.; Soh, C.P.; Wickham, T.J.; Roelvink, P.W.; Kovesdi, I.; Sutton, B.J.; Santis, G. Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J. Virol. 2000, 74, 2804-2813.
29. Roelvink, P.W.; Lizonova, A.; Lee, J.G.; Li, Y.; Bergelson, J.M.; Finberg, R.W.; Brough, D.E.; Kovesdi, I.; Wickham, T.J. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 1998, 72, 7909-7915.
30. Roelvink, P.W.; Mi Lee, G.; Einfeld, D.A.; Kovesdi, I.; Wickham, T.J. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999, 286, 1568-1571.
31. Santis, G.; Legrand, V.; Hong, S.S.; Davison, E.; Kirby, I.; Imler, J.L.; Finberg, R.W.; Bergelson, J.M.; Mehtali, M.; Boulanger, P. Molecular determinants of adenovirus serotype 5 fibre binding to its cellular receptor CAR. J. Gen. Virol. 1999, 80 (Pt 6), 1519-1527.
32. Tomko, R.P.; Xu, R.; Philipson, L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 3352-3356.
33. Wickham, T.J.; Mathias, P.; Cheresh, D.A.; Nemerow, G.R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993, 73, 309-319.
34. Li, E.; Stupack, D.; Klemke, R.; Cheresh, D.A.; Nemerow, G.R. Adenovirus endocytosis via alpha(v) integrins requires phosphoinositide-3-OH kinase. J. Virol. 1998, 72, 2055-2061.
35. Li, E.; Stupack, D.; Bokoch, G.M.; Nemerow, G.R. Adenovirus endocytosis requires actin cytoskeleton reorganization mediated by Rho family GTPases. J. Virol. 1998, 72, 8806-8812.
36. Bhat, N.R.; Fan, F. Adenovirus infection induces microglial activation: involvement of mitogenactivated protein kinase pathways. Brain Res. 2002, 948, 93-101.
37. Tibbles, L.A.; Spurrell, J.C.; Bowen, G.P.; Liu, Q.; Lam, M.; Zaiss, A.K.; Robbins, S.M.; Hollenberg, M.D.; Wickham, T.J.; Muruve, D.A. Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10. J. Virol. 2002, 76, 1559-1568.
38. Suomalainen, M.; Nakano, M.Y.; Keller, S.; Boucke, K.; Stidwill, R.P.; Greber, U.F. Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus. J. Cell Biol. 1999, 144, 657-672.
39. Farmer, C.; Morton, P.E.; Snippe, M.; Santis, G.; Parsons, M. Coxsackie adenovirus receptor (CAR) regulates integrin function through activation of p44/42 MAPK. Exp. Cell Res. 2009, 315, 2637-2647.
40. Meier, O.; Boucke, K.; Hammer, S.V.; Keller, S.; Stidwill, R.P.; Hemmi, S.; Greber, U.F. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J. Cell Biol. 2002, 158, 1119-1131.
41. Wang, K.; Huang, S.; Kapoor-Munshi, A.; Nemerow, G. Adenovirus internalization and infection require dynamin. J. Virol. 1998, 72, 3455-3458.
42. Greber, U.F.; Willetts, M.; Webster, P.; Helenius, A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 1993, 75, 477-486.
43. Dales, S.; Chardonnet, Y. Early events in the interaction of adenoviruses with HeLa cells. IV. Association with microtubules and the nuclear pore complex during vectorial movement of the inoculum. Virology 1973, 56, 465-483.
44. Wiethoff, C.M.; Wodrich, H.; Gerace, L.; Nemerow, G.R. Adenovirus protein VI mediates membrane disruption following capsid disassembly. J. Virol. 2005, 79, 1992-2000.
45. Kelkar, S.A.; Pfister, K.K.; Crystal, R.G.; Leopold, P.L. Cytoplasmic dynein mediates adenovirus binding to microtubules. J. Virol. 2004, 78, 10122-10132.
46. Leopold, P.L.; Kreitzer, G.; Miyazawa, N.; Rempel, S.; Pfister, K.K.; Rodriguez-Boulan, E.; Crystal, R.G. Dynein- and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum. Gene Ther. 2000, 11, 151-165.
47. Greber, U.F.; Suomalainen, M.; Stidwill, R.P.; Boucke, K.; Ebersold, M.W.; Helenius, A. The role of the nuclear pore complex in adenovirus DNA entry. EMBO J. 1997, 16, 5998-6007.
48. Trotman, L.C.; Mosberger, N.; Fornerod, M.; Stidwill, R.P.; Greber, U.F. Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat. Cell Biol. 2001, 3, 1092-1100.
49. Dechecchi, M.C.; Melotti, P.; Bonizzato, A.; Santacatterina, M.; Chilosi, M.; Cabrini, G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J. Virol. 2001, 75, 8772-8780.
50. Dechecchi, M.C.; Tamanini, A.; Bonizzato, A.; Cabrini, G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 2000, 268, 382-390.
51. Chu, Y.; Heistad, D.; Cybulsky, M.I.; Davidson, B.L. Vascular cell adhesion molecule-1 augments adenovirus-mediated gene transfer. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 238-242.
52. Hong, S.S.; Karayan, L.; Tournier, J.; Curiel, D.T.; Boulanger, P.A. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J. 1997, 16, 2294-2306.
53. Davison, E.; Kirby, I.; Elliott, T.; Santis, G. The human HLA-A*0201 allele, expressed in hamster cells, is not a high-affinity receptor for adenovirus type 5 fiber. J. Virol. 1999, 73, 4513-4517.
54. McDonald, D.; Stockwin, L.; Matzow, T.; Blair Zajdel, M.E.; Blair, G.E. Coxsackie and adenovirus receptor (CAR)-dependent and major histocompatibility complex (MHC) class I-independent uptake of recombinant adenoviruses into human tumour cells. Gene Ther. 1999, 6, 1512-1519.
55. Huang, S.; Kamata, T.; Takada, Y.; Ruggeri, Z.M.; Nemerow, G.R. Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J. Virol. 1996, 70, 4502-4508.
56. Davison, E.; Kirby, I.; Whitehouse, J.; Hart, I.; Marshall, J.F.; Santis, G. Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by alpha(v)beta1 integrin and can be modulated by changes in beta1 integrin function. J. Gene. Med. 2001, 3, 550-559.
57. Davison, E.; Diaz, R.M.; Hart, I.R.; Santis, G.; Marshall, J.F. Integrin alpha5beta1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16. J. Virol. 1997, 71, 6204-6207.
58. Li, E.; Brown, S.L.; Stupack, D.G.; Puente, X.S.; Cheresh, D.A.; Nemerow, G.R. Integrin alpha(v)beta1 is an adenovirus coreceptor. J. Virol. 2001, 75, 5405-5409.
59. Salone, B.; Martina, Y.; Piersanti, S.; Cundari, E.; Cherubini, G.; Franqueville, L.; Failla, C.M.; Boulanger, P.; Saggio, I. Integrin alpha3beta1 is an alternative cellular receptor for adenovirus serotype 5. J. Virol. 2003, 77, 13448-13454.
60. Alba, R.; Bradshaw, A.C.; Parker, A.L.; Bhella, D.; Waddington, S.N.; Nicklin, S.A.; van Rooijen, N.; Custers, J.; Goudsmit, J.; Barouch, D.H.; McVey, J.H.; Baker, A.H. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 2009, 114, 965-971.
61. Kalyuzhniy, O.; Di Paolo, N.C.; Silvestry, M.; Hofherr, S.E.; Barry, M.A.; Stewart, P.L.; Shayakhmetov, D.M. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 5483-5488.
62. Parker, A.L.; McVey, J.H.; Doctor, J.H.; Lopez-Franco, O.; Waddington, S.N.; Havenga, M.J.; Nicklin, S.A.; Baker, A.H. Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. J. Virol. 2007, 81, 3627-3631.
63. Parker, A.L.; Waddington, S.N.; Nicol, C.G.; Shayakhmetov, D.M.; Buckley, S.M.; Denby, L.; Kemball-Cook, G.; Ni, S.; Lieber, A.; McVey, J.H.; Nicklin, S.A.; Baker, A.H. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 2006, 108, 2554-2561.
64. Vigant, F.; Descamps, D.; Jullienne, B.; Esselin, S.; Connault, E.; Opolon, P.; Tordjmann, T.; Vigne, E.; Perricaudet, M.; Benihoud, K. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol. Ther. 2008, 16, 1474-1480.
65. Shayakhmetov, D.M.; Gaggar, A.; Ni, S.; Li, Z.Y.; Lieber, A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 2005, 79, 7478-7491.
66. Waddington, S.; McVey, J.; Bhella, D.; Parker, A.; Barker, K.; Atoda, H.; Pink, R.; Buckley, S.; Greig, J.; Denby, L.; Custers, J.; Morita, T.; Francischetti, I.; Monteiro, R.; Barouch, D.; Van Rooijen, N.; Napoli, C.; Havenga, M.; Nicklin, S.; Baker, A. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132, 397-409.
67. Bradshaw, A.C.; Parker, A.L.; Duffy, M.R.; Coughlan L.; Van Rooijen, N.; Kähäri, V.M.; Nicklin, S.A.; Baker, A.H. Requirements for Receptor Engagement during Infection by Adenovirus Complexed with Blood Coagulation Factor X. PLoS Pathog. 2010, doi:10.1371/journal.ppat.1001142.
68. Jonsson, M.I.; Lenman, A.E.; Frangsmyr, L.; Nyberg, C.; Abdullahi, M.; Arnberg, N. Coagulation factors IX and X enhance binding and infection of adenovirus types 5 and 31 in human epithelial cells. J. Virol. 2009, 83, 3816-3825.
69. Johansson, C.; Jonsson, M.; Marttila, M.; Persson, D.; Fan, X.L.; Skog, J.; Frangsmyr, L.; Wadell, G.; Arnberg, N. Adenoviruses use lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells. J. Virol. 2007, 81, 954-963.
70. Adams, W.C.; Bond, E.; Havenga, M.J.; Holterman, L.; Goudsmit, J.; Karlsson Hedestam, G.B.; Koup, R.A.; Lore, K. Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN. J. Gen. Virol. 2009, 90, 1600-1610.
71. Liu, Q.; Muruve, D.A. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 2003, 10, 935-940.
72. Liu, Q.; Zaiss, A.K.; Colarusso, P.; Patel, K.; Haljan, G.; Wickham, T.J.; Muruve, D.A. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum. Gene Ther. 2003, 14, 627-643.
73. Lieber, A.; He, C.Y.; Meuse, L.; Schowalter, D.; Kirillova, I.; Winther, B.; Kay, M.A. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 1997, 71, 8798-8807.
74. Alemany, R.; Suzuki, K.; Curiel, D.T. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 2000, 81, 2605-2609.
75. Nicol, C.G.; Graham, D.; Miller, W.H.; White, S.J.; Smith, T.A.; Nicklin, S.A.; Stevenson, S.C.; Baker, A.H. Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol. Ther. 2004, 10, 344-354.
76. Worgall, S.; Wolff, G.; Falck-Pedersen, E.; Crystal, R.G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 1997, 8, 37-44.
77. Di Paolo, N.C.; van Rooijen, N.; Shayakhmetov, D.M. Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver. Mol. Ther. 2009, 17, 675-684.
78. Haisma, H.J.; Boesjes, M.; Beerens, A.M.; van der Strate, B.W.; Curiel, D.T.; Pluddemann, A.; Gordon, S.; Bellu, A.R. Scavenger Receptor A: A New Route for Adenovirus 5. Mol. Pharmacol. 2009, 6, 366-374.
79. Stone, D.; Liu, Y.; Shayakhmetov, D.; Li, Z.Y.; Ni, S.; Lieber, A. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J. Virol. 2007, 81, 4866-4871.
80. Shayakhmetov, D.M.; Li, Z.Y.; Ni, S.; Lieber, A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol. 2004, 78, 5368-5381.
81. Carlisle, R.C.; Di, Y.; Cerny, A.M.; Sonnen, A.F.; Sim, R.B.; Green, N.K.; Subr, V.; Ulbrich, K.; Gilbert, R.J.; Fisher, K.D.; Finberg, R.W.; Seymour, L.W. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 2009, 113, 1909-1918.
82. Seiradake, E.; Henaff, D.; Wodrich, H.; Billet, O.; Perreau, M.; Hippert, C.; Mennechet, F.; Schoehn, G.; Lortat-Jacob, H.; Dreja, H.; Ibanes, S.; Kalatzis, V.; Wang, J.P.; Finberg, R.W.; Cusack, S.; Kremer, E.J. The cell adhesion molecule CAR and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog. 2009, 5, e1000277.
83. Xu, Z.; Tian, J.; Smith, J.S.; Byrnes, A.P. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J. Virol. 2008, 82, 11705-11713.
84. Onion, D.; Crompton, L.J.; Milligan, D.W.; Moss, P.A.; Lee, S.P.; Mautner, V. The CD4+ T-cell response to adenovirus is focused against conserved residues within the hexon protein. J. Gen. Virol. 2007, 88, 2417-2425.
85. Othman, M.; Labelle, A.; Mazzetti, I.; Elbatarny, H.S.; Lillicrap, D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 2007, 109, 2832-2839.
86. Wolff, G.; Worgall, S.; van Rooijen, N.; Song, W.R.; Harvey, B G.; Crystal, R.G. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J. Virol. 1997, 71, 624-629.
87. Kuzmin, A.I.; Finegold, M.J.; Eisensmith, R.C. Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther. 1997, 4, 309-316.
88. Schiedner, G.; Hertel, S.; Johnston, M.; Dries, V.; van Rooijen, N.; Kochanek, S. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol. Ther. 2003, 7, 35-43.
89. Kiang, A.; Hartman, Z.C.; Everett, R.S.; Serra, D.; Jiang, H.; Frank, M.M.; Amalfitano, A. Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol. Ther. 2006, 14, 588-598.
90. Cichon, G.; Schmidt, H.H.; Benhidjeb, T.; Loser, P.; Ziemer, S.; Haas, R.; Grewe, N.; Schnieders, F.; Heeren, J.; Manns, M.P.; Schlag, P.M.; Strauss, M. Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits. J. Gene Med. 1999, 1, 360-371.
91. Wolins, N.; Lozier, J.; Eggerman, T.L.; Jones, E.; Aguilar-Cordova, E.; Vostal, J.G. Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance. Br. J. Haematol. 2003, 123, 903-905.
92. Cotter, M. J.; Zaiss, A. K.; Muruve, D. A. Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. J. Virol. 2005, 79, 14622-14631.
93. Lyons, M.; Onion, D.; Green, N.K.; Aslan, K.; Rajaratnam, R.; Bazan-Peregrino, M.; Phipps, S.; Hale, S.; Mautner, V.; Seymour, L.W.; Fisher, K.D. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol. Ther. 2006, 14, 118-128.
94. Schiedner, G.; Bloch, W.; Hertel, S.; Johnston, M.; Molojavyi, A.; Dries, V.; Varga, G.; Van Rooijen, N.; Kochanek, S. A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum. Gene Ther. 2003, 14, 1631-1641.
95. O'Shea, C.C.; Johnson, L.; Bagus, B.; Choi, S.; Nicholas, C.; Shen, A.; Boyle, L.; Pandey, K.; Soria, C.; Kunich, J.; Shen, Y.; Habets, G.; Ginzinger, D.; McCormick, F. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004, 6, 611-623.
96. Fueyo, J.; Gomez-Manzano, C.; Alemany, R.; Lee, P.S.; McDonnell, T.J.; Mitlianga, P.; Shi, Y.X.; Levin, V.A.; Yung, W.K.; Kyritsis, A.P. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000, 19, 2-12.
97. Bauerschmitz, G.J.; Guse, K.; Kanerva, A.; Menzel, A.; Herrmann, I.; Desmond, R.A.; Yamamoto, M.; Nettelbeck, D.M.; Hakkarainen, T.; Dall, P.; Curiel, D.T.; Hemminki, A. Tripletargeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol. Ther. 2006, 14, 164-174.
98. Hernandez-Alcoceba, R.; Pihalja, M.; Wicha, M.S.; Clarke, M.F. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1adeleted adenoviral vectors. Hum. Gene Ther. 2000, 11, 2009-2024.
99. Tsukuda, K.; Wiewrodt, R.; Molnar-Kimber, K.; Jovanovic, V.P.; Amin, K.M. An E2Fresponsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res. 2002, 62, 3438-3447.
100. Lockley, M.; Fernandez, M.; Wang, Y.; Li, N.F.; Conroy, S.; Lemoine, N.; McNeish, I. Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wildtype viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res. 2006, 66, 989-998.
101. Sherr, C.J.; McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2, 103-112.
102. Morelli, A.E.; Larregina, A.T.; Smith-Arica, J.; Dewey, R.A.; Southgate, T.D.; Ambar, B.; Fontana, A.; Castro, M.G.; Lowenstein, P.R. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J. Gen. Virol. 1999, 80 (Pt 3), 571-583.
103. Gou, D.; Narasaraju, T.; Chintagari, N.R.; Jin, N.; Wang, P.; Liu, L. Gene silencing in alveolar type II cells using cell-specific promoter in vitro and in vivo. Nucleic Acids Res. 2004, 32, e134.
104. Nicklin, S.A.; Reynolds, P.N.; Brosnan, M.J.; White, S.J.; Curiel, D.T.; Dominiczak, A.F.; Baker, A.H. Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension 2001, 38, 65-70.
105. Work, L.M.; Ritchie, N.; Nicklin, S.A.; Reynolds, P.N.; Baker, A.H. Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 fibers and cell-selective transcriptional control. Gene Ther. 2004, 11, 1296-1300.
106. Anders, M.; Vieth, M.; Rocken, C.; Ebert, M.; Pross, M.; Gretschel, S.; Schlag, P.M.; Wiedenmann, B.; Kemmner, W.; Hocker, M. Loss of the coxsackie and adenovirus receptor contributes to gastric cancer progression. Br. J. Cancer. 2009, 100, 352-359.
107. Jee, Y.S.; Lee, S.G.; Lee, J.C.; Kim, M.J.; Lee, J.J.; Kim, D.Y.; Park, S.W.; Sung, M.W.; Heo, D.S. Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients. Anti-Cancer Res. 2002, 22, 2629-2634.
108. Matsumoto, K.; Shariat, S.F.; Ayala, G.E.; Rauen, K.A.; Lerner, S.P. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology 2005, 66, 441-446.
109. Mikami, T.; Ookawa, K.; Shimoyama, T.; Fukuda, S.; Saito, H.; Munakata, A. KAI1, CAR, and Smad4 expression in the progression of colorectal tumor. J. Gastroenterol. 2001, 36, 465-469.
110. Rauen, K.A.; Sudilovsky, D.; Le, J.L.; Chew, K.L.; Hann, B.; Weinberg, V.; Schmitt, L.D.; McCormick, F. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res. 2002, 62, 3812-3818.
111. Sachs, M.D.; Rauen, K.A.; Ramamurthy, M.; Dodson, J.L.; De Marzo, A.M.; Putzi, M.J.; Schoenberg, M.P.; Rodriguez, R. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology 2002, 60, 531-536.
112. Vincent, T.; Neve, E.P.; Johnson, J.R.; Kukalev, A.; Rojo, F.; Albanell, J.; Pietras, K.; Virtanen, I.; Philipson, L.; Leopold, P.L.; Crystal, R.G.; de Herreros, A.G.; Moustakas, A.; Pettersson, R.F.; Fuxe, J. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat. Cell Biol. 2009, 11, 943-950.
113. Douglas, J.T.; Kim, M.; Sumerel, L.A.; Carey, D.E.; Curiel, D.T. Efficient oncolysis by a replicating adenovirus (Ad) in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res. 2001, 61, 813-817.
114. Li, D.; Duan, L.; Freimuth, P.; O'Malley, B.W., Jr. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin. Cancer Res. 1999, 5, 4175-4181.
115. Li, Y.; Pong, R.C.; Bergelson, J.M.; Hall, M.C.; Sagalowsky, A.I.; Tseng, C.P.; Wang, Z.; Hsieh, J.T. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 1999, 59, 325-330.
116. Abbink, P.; Lemckert, A.A.; Ewald, B.A.; Lynch, D.M.; Denholtz, M.; Smits, S.; Holterman, L.; Damen, I.; Vogels, R.; Thorner, A.R.; O'Brien, K.L.; Carville, A.; Mansfield, K.G.; Goudsmit, J.; Havenga, M.J.; Barouch, D.H. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 2007, 81, 4654-4663.
117. Gaggar, A.; Shayakhmetov, D.M.; Lieber, A. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 2003, 9, 1408-1412.
118. Short, J.J.; Vasu, C.; Holterman, M.J.; Curiel, D.T.; Pereboev, A. Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res. 2006, 122, 144-153.
119. Tuve, S.; Wang, H.; Ware, C.; Liu, Y.; Gaggar, A.; Bernt, K.; Shayakhmetov, D.; Li, Z.; Strauss, R.; Stone, D.; Lieber, A. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J. Virol. 2006, 80, 12109-12120.
120. Arnberg, N.; Edlund, K.; Kidd, A.H.; Wadell, G. Adenovirus type 37 uses sialic acid as a cellular receptor. J. Virol. 2000, 74, 42-48.
121. Burmeister, W.P.; Guilligay, D.; Cusack, S.; Wadell, G.; Arnberg, N. Crystal structure of species D adenovirus fiber knobs and their sialic acid binding sites. J. Virol. 2004, 78, 7727-7736.
122. Arnberg, N.; Kidd, A.H.; Edlund, K.; Olfat, F.; Wadell, G. Initial interactions of subgenus D adenoviruses with A549 cellular receptors: sialic acid versus alpha(v) integrins. J. Virol. 2000, 74, 7691-7693.
123. Mathis, J.M.; Stoff-Khalili, M.A.; Curiel, D.T. Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene 2005, 24, 7775-7791.
124. Kurachi, S.; Tashiro, K.; Sakurai, F.; Sakurai, H.; Kawabata, K.; Yayama, K.; Okamoto, H.; Nakagawa, S.; Mizuguchi, H. Fiber-modified adenovirus vectors containing the TAT peptide derived from HIV-1 in the fiber knob have efficient gene transfer activity. Gene Ther. 2007, 14, 1160-1165.
125. Kurachi, S.; Koizumi, N.; Sakurai, F.; Kawabata, K.; Sakurai, H.; Nakagawa, S.; Hayakawa, T.; Mizuguchi, H. Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon. Gene Ther. 2007, 14, 266-274.
126. Belousova, N.; Krendelchtchikova, V.; Curiel, D.T.; Krasnykh, V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J. Virol. 2002, 76, 8621-8631.
127. Krasnykh, V.; Dmitriev, I.; Mikheeva, G.; Miller, C.R.; Belousova, N.; Curiel, D.T. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol. 1998, 72, 1844-1852.
128. Dmitriev, I.; Krasnykh, V.; Miller, C.R.; Wang, M.; Kashentseva, E.; Mikheeva, G.; Belousova, N.; Curiel, D.T. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 1998, 72, 9706-9713.
129. Wickham, T.J.; Segal, D.M.; Roelvink, P.W.; Carrion, M.E.; Lizonova, A.; Lee, G.M.; Kovesdi, I. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol. 1996, 70, 6831-6838.
130. Einfeld, D.A.; Brough, D.E.; Roelvink, P.W.; Kovesdi, I.; Wickham, T.J. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J. Virol. 1999, 73, 9130-9136.
131. Wu, H.; Han, T.; Belousova, N.; Krasnykh, V.; Kashentseva, E.; Dmitriev, I.; Kataram, M.; Mahasreshti, P.J.; Curiel, D.T. Identification of sites in adenovirus hexon for foreign peptide incorporation. J. Virol. 2005, 79, 3382-3390.
132. Campos, S.K.; Parrott, M.B.; Barry, M.A. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol. Ther. 2004, 9, 942-954.
133. Le, L.P.; Everts, M.; Dmitriev, I.P.; Davydova, J.G.; Yamamoto, M.; Curiel, D.T. Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol. Imaging. 2004, 3, 105-116.
134. Le, L.P.; Li, J.; Ternovoi, V.V.; Siegal, G.P.; Curiel, D.T. Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein. J. Gen. Virol. 2005, 86, 3201-3208.
135. Meulenbroek, R.A.; Sargent, K.L.; Lunde, J.; Jasmin, B.J.; Parks, R.J. Use of adenovirus protein IX (pIX) to display large polypeptides on the virion-generation of fluorescent virus through the incorporation of pIX-GFP. Mol. Ther. 2004, 9, 617-624.
136. Krasnykh, V.; Belousova, N.; Korokhov, N.; Mikheeva, G.; Curiel, D.T. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J. Virol. 2001, 75, 4176-4183.
137. Belousova, N.; Mikheeva, G.; Gelovani, J.; Krasnykh, V. Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. J. Virol. 2008, 82, 630-637.
138. Magnusson, M.K.; Hong, S.S.; Henning, P.; Boulanger, P.; Lindholm, L. Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viability. J. Gene Med. 2002, 4, 356-370.
139. Michael, S.I.; Hong, J.S.; Curiel, D.T.; Engler, J.A. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther. 1995, 2, 660-668.
140. Gaden, F.; Franqueville, L.; Hong, S.S.; Legrand, V.; Figarella, C.; Boulanger, P. Mechanism of restriction of normal and cystic fibrosis transmembrane conductance regulator-deficient human tracheal gland cells to adenovirus infection and ad-mediated gene transfer. Am. J. Respir. Cell Mol. Biol. 2002, 27, 628-640.
141. Wickham, T.J.; Roelvink, P.W.; Brough, D.E.; Kovesdi, I. Adenovirus targeted to heparancontaining receptors increases its gene delivery efficiency to multiple cell types. Nat. Biotechnol. 1996, 14, 1570-1573.
142. Wickham, T.J.; Tzeng, E.; Shears, L.L., II; Roelvink, P.W.; Li, Y.; Lee, G.M.; Brough, D.E.; Lizonova, A.; Kovesdi, I. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 1997, 71, 8221-8229.
143. Yoshida, Y.; Sadata, A.; Zhang, W.; Saito, K.; Shinoura, N.; Hamada, H. Generation of fibermutant recombinant adenoviruses for gene therapy of malignant glioma. Hum. Gene Ther. 1998, 9, 2503-2515.
144. Han, T.; Tang, Y.; Ugai, H.; Perry, L.E.; Siegal, G.P.; Contreras, J.L.; Wu, H. Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy. Virol. J. 2007, 4, 103.
145. Hong, J.S.; Engler, J.A. Domains required for assembly of adenovirus type 2 fiber trimers. J. Virol. 1996, 70, 7071-7078.
146. Parrott, M.B.; Adams, K.E.; Mercier, G.T.; Mok, H.; Campos, S.K.; Barry, M.A. Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. Mol. Ther. 2003, 8, 688-700.
147. Xia, D.; Henry, L.J.; Gerard, R.D.; Deisenhofer, J. Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure 1994, 2, 1259-1270.
148. Einfeld, D.A.; Schroeder, R.; Roelvink, P.W.; Lizonova, A.; King, C.R.; Kovesdi, I.; Wickham, T. J. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol. 2001, 75, 11284-11291.
149. Coughlan, L.; Vallath, S.; Saha, A.; Flak, M.; McNeish, I.A.; Vassaux, G.; Marshall, J.F.; Hart, I.R.; Thomas, G.J. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J. Virol. 2009, 83, 6416-6428.
150. van Geer, M.A.; Bakker, C.T.; Koizumi, N.; Mizuguchi, H.; Wesseling, J.G.; Oude Elferink, R.P.; Bosma, P.J. Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo. World J. Gastroenterol. 2009, 15, 2754-2762.
151. Ruoslahti, E.; Bhatia, S.N.; Sailor, M.J. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 2010, 188, 759-768.
152. Majhen, D.; Gabrilovac, J.; Eloit, M.; Richardson, J.; Ambriovic-Ristov, A. Disulfide bond formation in NGR fiber-modified adenovirus is essential for retargeting to aminopeptidase N. Biochem. Biophys. Res. Commun. 2006, 348, 278-287.
153. Gaden, F.; Franqueville, L.; Magnusson, M.K.; Hong, S.S.; Merten, M.D.; Lindholm, L.; Boulanger, P. Gene transduction and cell entry pathway of fiber-modified adenovirus type 5 vectors carrying novel endocytic peptide ligands selected on human tracheal glandular cells. J. Virol. 2004, 78, 7227-7247.
154. Xia, H.; Anderson, B.; Mao, Q.; Davidson, B.L. Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J. Virol. 2000, 74, 11359-11366.
155. Joung, I.; Harber, G.; Gerecke, K.M.; Carroll, S.L.; Collawn, J.F.; Engler, J.A. Improved gene delivery into neuroglial cells using a fiber-modified adenovirus vector. Biochem. Biophys. Res. Commun. 2005, 328, 1182-1187.
156. Nicklin, S.A.; Von Seggern, D.J.; Work, L.M.; Pek, D.C.; Dominiczak, A.F.; Nemerow, G.R.; Baker, A.H. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol. Ther. 2001, 4, 534-542.
157. Work, L.M.; Nicklin, S.A.; Brain, N.J.; Dishart, K.L.; Von Seggern, D.J.; Hallek, M.; Buning, H.; Baker, A.H. Development of efficient viral vectors selective for vascular smooth muscle cells. Mol. Ther. 2004, 9, 198-208.
158. Denby, L.; Work, L.M.; Seggern, D.J.; Wu, E.; McVey, J.H.; Nicklin, S.A.; Baker, A.H. Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. Mol. Ther. 2007, 15, 1647-1654.
159. Cripe, T.P.; Dunphy, E.J.; Holub, A.D.; Saini, A.; Vasi, N.H.; Mahller, Y.Y.; Collins, M.H.; Snyder, J.D.; Krasnykh, V.; Curiel, D.T.; Wickham, T.J.; DeGregori, J.; Bergelson, J.M.; Currier, M.A. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirusadenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 2001, 61, 2953-2960.
160. Grill, J.; Van Beusechem, V.W.; Van Der Valk, P.; Dirven, C.M.; Leonhart, A.; Pherai, D.S.; Haisma, H.J.; Pinedo, H.M.; Curiel, D.T.; Gerritsen, W.R. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin. Cancer Res. 2001, 7, 641-650.
161. Nagel, H.; Maag, S.; Tassis, A.; Nestle, F.O.; Greber, U.F.; Hemmi, S. The alphavbeta5 integrin of hematopoietic and nonhematopoietic cells is a transduction receptor of RGD-4C fiber modified adenoviruses. Gene Ther. 2003, 10, 1643-1653.
162. Wesseling, J.G.; Bosma, P.J.; Krasnykh, V.; Kashentseva, E.A.; Blackwell, J.L.; Reynolds, P.N.; Li, H.; Parameshwar, M.; Vickers, S.M.; Jaffee, E.M.; Huibregtse, K.; Curiel, D.T.; Dmitriev, I. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther. 2001, 8, 969-976.
163. Reynolds, P.; Dmitriev, I.; Curiel, D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther. 1999, 6, 1336-1339.
164. Gonzalez, R.; Vereecque, R.; Wickham, T.J.; Facon, T.; Hetuin, D.; Kovesdi, I.; Bauters, F.; Fenaux, P.; Quesnel, B. Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells. Hum. Gene Ther. 1999, 10, 2709-2717.
165. Ranki, T.; Kanerva, A.; Ristimaki, A.; Hakkarainen, T.; Sarkioja, M.; Kangasniemi, L.; Raki, M.; Laakkonen, P.; Goodison, S.; Hemminki, A. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther. 2007, 14, 58-67.
166. Rein, D.T.; Breidenbach, M.; Wu, H.; Han, T.; Haviv, Y.S.; Wang, M.; Kirby, T.O.; Kawakami, Y.; Dall, P.; Alvarez, R.D.; Curiel, D.T. Gene transfer to cervical cancer with fiber-modified adenoviruses. Int. J. Cancer 2004, 111, 698-704.
167. Staba, M.J.; Wickham, T.J.; Kovesdi, I.; Hallahan, D.E. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther. 2000, 7, 13-19.
168. Wu, H.; Seki, T.; Dmitriev, I.; Uil, T.; Kashentseva, E.; Han, T.; Curiel, D.T. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirusadenovirus receptor-independent gene transfer efficiency. Hum. Gene Ther. 2002, 13, 1647-1653.
169. Alderson, M.R.; Armitage, R.J.; Tough, T.W.; Strockbine, L.; Fanslow, W.C.; Spriggs, M.K. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J. Exp. Med. 1993, 178, 669-674.
170. Galy, A.H.; Spits, H. CD40 is functionally expressed on human thymic epithelial cells. J. Immunol. 1992, 149, 775-782.
171. Hsu, Y.M.; Lucci, J.; Su, L.; Ehrenfels, B.; Garber, E.; Thomas, D. Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes. J. Biol. Chem. 1997, 272, 911-915.
172. Sasisekharan, R.; Shriver, Z.; Venkataraman, G.; Narayanasami, U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2002, 2, 521-528.
173. Ahmed, N.; Riley, C.; Rice, G.E.; Quinn, M.A.; Baker, M.S. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J. Histochem. Cytochem. 2002, 50, 1371-1380.
174. Bates, R.C.; Bellovin, D.I.; Brown, C.; Maynard, E.; Wu, B.; Kawakatsu, H.; Sheppard, D.; Oettgen, P.; Mercurio, A.M. Transcriptional activation of integrin beta6 during the epithelialmesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J. Clin. Invest. 2005, 115, 339-347.
175. Elayadi, A.N.; Samli, K.N.; Prudkin, L.; Liu, Y.H.; Bian, A.; Xie, X.J.; Wistuba, II; Roth, J.A.; McGuire, M.J.; Brown, K.C. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 2007, 67, 5889-5895.
176. Hazelbag, S.; Kenter, G.G.; Gorter, A.; Dreef, E.J.; Koopman, L.A.; Violette, S.M.; Weinreb, P.H.; Fleuren, G.J. Overexpression of the alphavbeta6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J. Pathol. 2007, 212, 316-324.
177. Koizumi, N.; Mizuguchi, H.; Utoguchi, N.; Watanabe, Y.; Hayakawa, T. Generation of fiber modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. J. Gene Med. 2003, 5, 267-276.
178. Mizuguchi, H.; Koizumi, N.; Hosono, T.; Utoguchi, N.; Watanabe, Y.; Kay, M.A.; Hayakawa, T. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther. 2001, 8, 730-735.
179. Magnusson, M.K.; Henning, P.; Myhre, S.; Wikman, M.; Uil, T.G.; Friedman, M.; Andersson, K. M.; Hong, S.S.; Hoeben, R.C.; Habib, N.A.; Stahl, S.; Boulanger, P.; Lindholm, L. Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu. Cancer Gene Ther. 2007, 14, 468-479.
180. Binz, H.K.; Amstutz, P.; Pluckthun, A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 2005, 23, 1257-1268.
181. Henning, P.; Magnusson, M.K.; Gunneriusson, E.; Hong, S.S.; Boulanger, P.; Nygren, P.A.; Lindholm, L. Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A. Hum. Gene Ther. 2002, 13, 1427-1439.
182. Myhre, S.; Henning, P.; Friedman, M.; Stahl, S.; Lindholm, L.; Magnusson, M.K. Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber. Gene Ther. 2009, 16, 252-261.
183. Nord, K.; Gunneriusson, E.; Ringdahl, J.; Stahl, S.; Uhlen, M.; Nygren, P.A. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat. Biotechnol. 1997, 15, 772-777.
184. Menard, S.; Pupa, S.M.; Campiglio, M.; Tagliabue, E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003, 22, 6570-6578.
185. Legrand, V.; Spehner, D.; Schlesinger, Y.; Settelen, N.; Pavirani, A.; Mehtali, M. Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber. J. Virol. 1999, 73, 907-919.
186. Miyazawa, N.; Leopold, P.L.; Hackett, N.R.; Ferris, B.; Worgall, S.; Falck-Pedersen, E.; Crystal, R.G. Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. J. Virol. 1999, 73, 6056-6065.
187. Magnusson, M.K.; Hong, S.S.; Boulanger, P.; Lindholm, L. Genetic retargeting of adenovirus: novel strategy employing deknobbing of the fiber. J. Virol. 2001, 75, 7280-7289.
188. Shayakhmetov, D.M.; Li, Z.Y.; Ternovoi, V.; Gaggar, A.; Gharwan, H.; Lieber, A. The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J. Virol. 2003, 77, 3712-3723.
189. van Beusechem, V.W.; van Rijswijk, A.L.; van Es, H.H.; Haisma, H.J.; Pinedo, H.M.; Gerritsen, W.R. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Ther. 2000, 7, 1940-1946.
190. Schagen, F.H.; Wensveen, F.M.; Carette, J.E.; Dermody, T.S.; Gerritsen, W.R.; van Beusechem, V.W. Genetic targeting of adenovirus vectors using a reovirus sigma1-based attachment protein. Mol. Ther. 2006, 13, 997-1005.
191. Hedley, S.J.; Auf der Maur, A.; Hohn, S.; Escher, D.; Barberis, A.; Glasgow, J.N.; Douglas, J.T.; Korokhov, N.; Curiel, D.T. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther. 2006, 13, 88-94.
192. Belousova, N.; Korokhov, N.; Krendelshchikova, V.; Simonenko, V.; Mikheeva, G.; Triozzi, P. L.; Aldrich, W.A.; Banerjee, P.T.; Gillies, S.D.; Curiel, D.T.; Krasnykh, V. Genetically targeted adenovirus vector directed to CD40-expressing cells. J. Virol. 2003, 77, 11367-11377.
193. Izumi, M.; Kawakami, Y.; Glasgow, J.N.; Belousova, N.; Everts, M.; Kim-Park, S.; Yamamoto, S.; Wang, M.; Le, L.P.; Reynolds, P.N.; Curiel, D.T. In vivo analysis of a genetically modified adenoviral vector targeted to human CD40 using a novel transient transgenic model. J. Gene Med. 2005, 7, 1517-1525.
194. Li, J.; Lad, S.; Yang, G.; Luo, Y.; Iacobelli-Martinez, M.; Primus, F. J.; Reisfeld, R.A.; Li, E. Adenovirus fiber shaft contains a trimerization element that supports peptide fusion for targeted gene delivery. J. Virol. 2006, 80, 12324-12331.
195. Henning, P.; Lundgren, E.; Carlsson, M.; Frykholm, K.; Johannisson, J.; Magnusson, M.K.; Tang, E.; Franqueville, L.; Hong, S.S.; Lindholm, L.; Boulanger, P. Adenovirus type 5 fiber knob domain has a critical role in fiber protein synthesis and encapsidation. J. Gen. Virol. 2006, 87, 3151-3160.
196. Franqueville, L.; Henning, P.; Magnusson, M.; Vigne, E.; Schoehn, G.; Blair-Zajdel, M.E.; Habib, N.; Lindholm, L.; Blair, G.E.; Hong, S.S.; Boulanger, P. Protein crystals in Adenovirus type 5-infected cells: requirements for intranuclear crystallogenesis, structural and functional analysis. PLoS One 2008, 3, e2894.
197. Walters, R.W.; Freimuth, P.; Moninger, T.O.; Ganske, I.; Zabner, J.; Welsh, M.J. Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell 2002, 110, 789-799.
198. Hong, S.S.; Magnusson, M.K.; Henning, P.; Lindholm, L.; Boulanger, P.A. Adenovirus stripping: a versatile method to generate adenovirus vectors with new cell target specificity. Mol. Ther. 2003, 7, 692-699.
199. Bayo-Puxan, N.; Gimenez-Alejandre, M.; Lavilla-Alonso, S.; Gros, A.; Cascallo, M.; Hemminki, A.; Alemany, R. Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycanbinding domain with RGD for improved tumor infectivity and targeting. Hum. Gene Ther. 2009, 20, 1214-1221.
200. Athappilly, F.K.; Murali, R.; Rux, J.J.; Cai, Z.; Burnett, R.M. The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution. J. Mol. Biol. 1994, 242, 430-455.
201. Vigne, E.; Mahfouz, I.; Dedieu, J.F.; Brie, A.; Perricaudet, M.; Yeh, P. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J. Virol. 1999, 73, 5156-5161.
202. Crompton, J.; Toogood, C.I.; Wallis, N.; Hay, R.T. Expression of a foreign epitope on the surface of the adenovirus hexon. J. Gen. Virol. 1994, 75 (Pt 1), 133-139.
203. McConnell, M.J.; Danthinne, X.; Imperiale, M.J. Characterization of a permissive epitope insertion site in adenovirus hexon. J. Virol. 2006, 80, 5361-5370.
204. Campos, S.K.; Barry, M.A. Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda Red recombination. Hum. Gene Ther. 2004, 15, 1125-1130.
205. Kurachi, S.; Koizumi, N.; Tashiro, K.; Sakurai, H.; Sakurai, F.; Kawabata, K.; Nakagawa, S.; Mizuguchi, H. Modification of pIX or hexon based on fiberless Ad vectors is not effective for targeted Ad vectors. J. Controlled Release 2008, 127, 88-95.
206. Sumida, S.M.; Truitt, D.M.; Lemckert, A.A.; Vogels, R.; Custers, J.H.; Addo, M.M.; Lockman, S.; Peter, T.; Peyerl, F.W.; Kishko, M.G.; Jackson, S.S.; Gorgone, D.A.; Lifton, M.A.; Essex, M.; Walker, B.D.; Goudsmit, J.; Havenga, M.J.; Barouch, D.H. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 2005, 174, 7179-7185.
207. Vlachaki, M.T.; Hernandez-Garcia, A.; Ittmann, M.; Chhikara, M.; Aguilar, L.K.; Zhu, X.; Teh, B.S.; Butler, E.B.; Woo, S.; Thompson, T.C.; Barrera-Saldana, H.; Aguilar-Cordova, E. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol. Ther. 2002, 6, 342-348.
208. Varnavski, A.N.; Calcedo, R.; Bove, M.; Gao, G.; Wilson, J.M. Evaluation of toxicity from highdose systemic administration of recombinant adenovirus vector in vector-naive and preimmunized mice. Gene Ther. 2005, 12, 427-436.
209. Zubieta, C.; Schoehn, G.; Chroboczek, J.; Cusack, S. The structure of the human adenovirus 2 penton. Mol. Cell 2005, 17, 121-135.
210. Chiu, C.Y.; Mathias, P.; Nemerow, G.R.; Stewart, P.L. Structure of adenovirus complexed with its internalization receptor, alphavbeta5 integrin. J. Virol. 1999, 73, 6759-6768.
211. Wickham, T.J.; Carrion, M.E.; Kovesdi, I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther. 1995, 2, 750-756.
212. Boulanger, P.; Lemay, P.; Blair, G.E.; Russell, W.C. Characterization of adenovirus protein IX. J. Gen. Virol. 1979, 44, 783-800.
213. Stewart, P.L.; Burnett, R.M.; Cyrklaff, M.; Fuller, S.D. Image reconstruction reveals the complex molecular organization of adenovirus. Cell 1991, 67, 145-154.
214. Furcinitti, P.S.; van Oostrum, J.; Burnett, R.M. Adenovirus polypeptide IX revealed as capsid cement by difference images from electron microscopy and crystallography. EMBO J. 1989, 8, 3563-3570.
215. Ghosh-Choudhury, G.; Haj-Ahmad, Y.; Graham, F.L. Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. EMBO J. 1987, 6, 1733-1739.
216. Rosa-Calatrava, M.; Grave, L.; Puvion-Dutilleul, F.; Chatton, B.; Kedinger, C. Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization. J. Virol. 2001, 75, 7131-7141.
217. Sargent, K.L.; Meulenbroek, R.A.; Parks, R.J. Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. J. Virol. 2004, 78, 5032-5037.
218. Saban, S.D.; Silvestry, M.; Nemerow, G.R.; Stewart, P.L. Visualization of alpha-helices in a 6-angstrom resolution cryoelectron microscopy structure of adenovirus allows refinement of capsid protein assignments. J. Virol. 2006, 80, 12049-12059.
219. Marsh, M.P.; Campos, S.K.; Baker, M.L.; Chen, C.Y.; Chiu, W.; Barry, M.A. Cryoelectron microscopy of protein IX-modified adenoviruses suggests a new position for the C terminus of protein IX. J. Virol. 2006, 80, 11881-11886.
220. Dmitriev, I.P.; Kashentseva, E.A.; Curiel, D.T. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J. Virol. 2002, 76, 6893-6899.
221. Vellinga, J.; Rabelink, M.J.; Cramer, S.J.; van den Wollenberg, D.J.; Van der Meulen, H.; Leppard, K.N.; Fallaux, F.J.; Hoeben, R.C. Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX. J. Virol. 2004, 78, 3470-3479.
222. Campos, S.K.; Barry, M.A. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology 2006, 349, 453-462.
223. Li, J.; Le, L.; Sibley, D.A.; Mathis, J.M.; Curiel, D.T. Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology 2005, 338, 247-258.
224. Vellinga, J.; van den Wollenberg, D.J.; van der Heijdt, S.; Rabelink, M.J.; Hoeben, R.C. The coiled-coil domain of the adenovirus type 5 protein IX is dispensable for capsid incorporation and thermostability. J. Virol. 2005, 79, 3206-3210.
225. Barnett, B.G.; Crews, C.J.; Douglas, J.T. Targeted adenoviral vectors. Biochim. Biophys. Acta. 2002, 1575, 1-14.
226. Tarassishin, L.; Szawlowski, P.; Kidd, A.H.; Russell, W.C. An epitope on the adenovirus fibre tail is common to all human subgroups. Arch. Virol. 2000, 145, 805-811.
227. Stone, D.; Liu, Y.; Li, Z.Y.; Tuve, S.; Strauss, R.; Lieber, A. Comparison of adenoviruses from species B, C, E, and F after intravenous delivery. Mol. Ther. 2007, 15, 2146-2153.
228. Stone, D.; Ni, S.; Li, Z.Y.; Gaggar, A.; DiPaolo, N.; Feng, Q.; Sandig, V.; Lieber, A. Development and assessment of human adenovirus type 11 as a gene transfer vector. J. Virol. 2005, 79, 5090-5104.
229. Segerman, A.; Atkinson, J.P.; Marttila, M.; Dennerquist, V.; Wadell, G.; Arnberg, N. Adenovirus type 11 uses CD46 as a cellular receptor. J. Virol. 2003, 77, 9183-9191.
230. Tuve, S.; Wang, H.; Jacobs, J.D.; Yumul, R.C.; Smith, D.F.; Lieber, A. Role of cellular heparin sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. PLoS Pathog. 2008, 4, e1000189.
231. Rea, D.; Havenga, M.J.; van Den Assem, M.; Sutmuller, R.P.; Lemckert, A.; Hoeben, R.C.; Bout, A.; Melief, C.J.; Offringa, R. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 2001, 166, 5236-5244.
232. Havenga, M.J.; Lemckert, A.A.; Grimbergen, J.M.; Vogels, R.; Huisman, L.G.; Valerio, D.; Bout, A.; Quax, P.H. Improved adenovirus vectors for infection of cardiovascular tissues. J. Virol. 2001, 75, 3335-3342.
233. Shayakhmetov, D.M.; Papayannopoulou, T.; Stamatoyannopoulos, G.; Lieber, A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J. Virol. 2000, 74, 2567-2583.
234. Granio, O.; Ashbourne Excoffon, K.J.; Henning, P.; Melin, P.; Norez, C.; Gonzalez, G.; Karp, P.H.; Magnusson, M.K.; Habib, N.; Lindholm, L.; Becq, F.; Boulanger, P.; Zabner, J.; Hong, S.S. Adenovirus 5-fiber 35 chimeric vector mediates efficient apical correction of the cystic fibrosis transmembrane conductance regulator defect in cystic fibrosis primary airway epithelia. Hum. Gene Ther. 2010, 21, 251-269.
235. Walters, R.W.; Grunst, T.; Bergelson, J.M.; Finberg, R.W.; Welsh, M.J.; Zabner, J. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J. Biol. Chem. 1999, 274, 10219-10226.
236. Sinn, P.L.; Williams, G.; Vongpunsawad, S.; Cattaneo, R.; McCray, P.B., Jr. Measles virus preferentially transduces the basolateral surface of well-differentiated human airway epithelia. J. Virol. 2002, 76, 2403-2409.
237. Liu, Y.; Wang, H.; Yumul, R.; Gao, W.; Gambotto, A.; Morita, T.; Baker, A.; Shayakhmetov, D.; Lieber, A. Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatment. Hum. Gene Ther. 2009, 20, 621-629.
238. Toyoda, E.; Doi, R.; Kami, K.; Mori, T.; Ito, D.; Koizumi, M.; Kida, A.; Nagai, K.; Ito, T.; Masui, T.; Wada, M.; Tagawa, M.; Uemoto, S. Adenovirus vectors with chimeric type 5 and 35 fiber proteins exhibit enhanced transfection of human pancreatic cancer cells. Int J Oncol 2008, 33, 1141-1147.
239. Shayakhmetov, D.M.; Li, Z.Y.; Ni, S.; Lieber, A. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res. 2002, 62, 1063-1068.
240. Wang, H.; Liu, Y.; Li, Z.; Tuve, S.; Stone, D.; Kalyushniy, O.; Shayakhmetov, D.; Verlinde, C.L.; Stehle, T.; McVey, J.; Baker, A.; Peng, K.W.; Roffler, S.; Lieber, A. In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46. J. Virol. 2008, 82, 10567-10579.
241. Wang, G.; Li, G.; Liu, H.; Yang, C.; Yang, X.; Jin, J.; Liu, X.; Qian, Q.; Qian, W. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. J. Gene Med. 2009, 11, 477-485.
242. Alba, R.; Bradshaw, A.C.; Coughlan, L.; Denby, L.; McDonald, R.A.; Waddington, S.N.; Buckley, S.M.K.; Greig, J.A.; Parker, A.L.; Miller, A.M.; Wang, H.; Lieber, A.; van Rooijen, N.; McVey, J.H.; Nicklin, S.A.; Baker, A.H. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 2010, doi: 10.1182/blood-2009-12-260026.
243. Haviv, Y.S.; Blackwell, J.L.; Kanerva, A.; Nagi, P.; Krasnykh, V.; Dmitriev, I.; Wang, M.; Naito, S.; Lei, X.; Hemminki, A.; Carey, D.; Curiel, D.T. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res. 2002, 62, 4273-4281.
244. Kanerva, A.; Mikheeva, G.V.; Krasnykh, V.; Coolidge, C.J.; Lam, J.T.; Mahasreshti, P.J.; Barker, S.D.; Straughn, M.; Barnes, M.N.; Alvarez, R.D.; Hemminki, A.; Curiel, D.T. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. 2002, 8, 275-280.
245. Ulasov, I.V.; Rivera, A.A.; Han, Y.; Curiel, D.T.; Zhu, Z.B.; Lesniak, M.S. Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells. J. Neurosurg. 2007, 107, 617-627.
246. Volk, A.L.; Rivera, A.A.; Kanerva, A.; Bauerschmitz, G.; Dmitriev, I.; Nettelbeck, D.M.; Curiel, D.T. Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther 2003, 2, 511-515.
247. Von Seggern, D.J.; Huang, S.; Fleck, S.K.; Stevenson, S.C.; Nemerow, G.R. Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virustransformed B cells. J. Virol. 2000, 74, 354-362.
248. Raki, M.; Sarkioja, M.; Desmond, R.A.; Chen, D.T.; Butzow, R.; Hemminki, A.; Kanerva, A. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol. Oncol. 2008, 108, 166-172.
249. Guse, K.; Ranki, T.; Ala-Opas, M.; Bono, P.; Sarkioja, M.; Rajecki, M.; Kanerva, A.; Hakkarainen, T.; Hemminki, A. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Mol. Cancer Ther. 2007, 6, 2728-2736.
250. Nandi, S.; Ulasov, I.V.; Rolle, C.E.; Han, Y.; Lesniak, M.S. A chimeric adenovirus with an Ad3 fiber knob modification augments glioma virotherapy. J. Gene Med. 2009, 11, 1005-1011.
251. Rajecki, M.; Kanerva, A.; Stenman, U.H.; Tenhunen, M.; Kangasniemi, L.; Sarkioja, M.; Ala-Opas, M.Y.; Alfthan, H.; Sankila, A.; Rintala, E.; Desmond, R.A.; Hakkarainen, T.; Hemminki, A. Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Mol. Cancer Ther. 2007, 6, 742-751.
252. Ni, S.; Bernt, K.; Gaggar, A.; Li, Z.Y.; Kiem, H.P.; Lieber, A. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum. Gene Ther. 2005, 16, 664-677.
253. Hsu, C.; Boysen, M.; Gritton, L.D.; Frosst, P.D.; Nemerow, G.R.; Von Seggern, D.J. In vitro dendritic cell infection by pseudotyped adenoviral vectors does not correlate with their in vivo immunogenicity. Virology 2005, 332, 1-7.
254. Chiu, C.Y.; Wu, E.; Brown, S.L.; Von Seggern, D.J.; Nemerow, G.R.; Stewart, P.L. Structural analysis of a fiber-pseudotyped adenovirus with ocular tropism suggests differential modes of cell receptor interactions. J. Virol. 2001, 75, 5375-5380.
255. Denby, L.; Work, L.M.; Graham, D.; Hsu, C.; von Seggern, D.J.; Nicklin, S.A.; Baker, A.H. Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Hum. Gene Ther. 2004, 15, 1054-1064.
256. Diaconu, I.; Denby, L.; Pesonen, S.; Cerullo, V.; Bauerschmitz, G.J.; Guse, K.; Rajecki, M.; Dias, J.D.; Taari, K.; Kanerva, A.; Baker, A.H.; Hemminki, A. Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver. Hum. Gene Ther. 2009, 20, 611-620.
257. Hesse, A.; Kosmides, D.; Kontermann, R.E.; Nettelbeck, D.M. Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain. J. Virol. 2007, 81, 2688-2699.
258. Stoff-Khalili, M.A.; Rivera, A.A.; Glasgow, J.N.; Le, L.P.; Stoff, A.; Everts, M.; Tsuruta, Y.; Kawakami, Y.; Bauerschmitz, G.J.; Mathis, J.M.; Pereboeva, L.; Seigal, G.P.; Dall, P.; Curiel, D.T. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy. Gene Ther. 2005, 12, 1696-1706.
259. Nakayama, M.; Both, G.W.; Banizs, B.; Tsuruta, Y.; Yamamoto, S.; Kawakami, Y.; Douglas, J. T.; Tani, K.; Curiel, D.T.; Glasgow, J.N. An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR-independent tropism and unique biodistribution in mice. Virology 2006, 350, 103-115.
260. Rogee, S.; Grellier, E.; Bernard, C.; Jouy, N.; Loyens, A.; Beauvillain, J.C.; Fender, P.; Corjon, S.; Hong, S.S.; Boulanger, P.; Quesnel, B.; D'Halluin, J.C.; Colin, M. Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response. Gene Ther. 2010, doi:10.1038/gt.2010.37.
261. Tsuruta, Y.; Pereboeva, L.; Glasgow, J.N.; Luongo, C.L.; Komarova, S.; Kawakami, Y.; Curiel, D.T. Reovirus sigma1 fiber incorporated into adenovirus serotype 5 enhances infectivity via a CAR-independent pathway. Biochem. Biophys. Res. Commun. 2005, 335, 205-214.
262. Mercier, G.T.; Campbell, J.A.; Chappell, J.D.; Stehle, T.; Dermody, T.S.; Barry, M.A. A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 6188-6193.
263. Barton, E.S.; Forrest, J.C.; Connolly, J.L.; Chappell, J.D.; Liu, Y.; Schnell, F.J.; Nusrat, A.; Parkos, C.A.; Dermody, T.S. Junction adhesion molecule is a receptor for reovirus. Cell 2001, 104, 441-451.
264. Chappell, J.D.; Gunn, V.L.; Wetzel, J.D.; Baer, G.S.; Dermody, T.S. Mutations in type 3 reovirus that determine binding to sialic acid are contained in the fibrous tail domain of viral attachment protein sigma1. J. Virol. 1997, 71, 1834-1841.
265. Miyazawa, N.; Crystal, R.G.; Leopold, P.L. Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein. J. Virol. 2001, 75, 1387-1400.
266. Glasgow, J.N.; Everts, M.; Curiel, D.T. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther. 2006, 13, 830-844.
267. Korokhov, N.; Mikheeva, G.; Krendelshchikov, A.; Belousova, N.; Simonenko, V.; Krendelshchikova, V.; Pereboev, A.; Kotov, A.; Kotova, O.; Triozzi, P.L.; Aldrich, W.A.; Douglas, J.T.; Lo, K.M.; Banerjee, P.T.; Gillies, S.D.; Curiel, D.T.; Krasnykh, V. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J. Virol. 2003, 77, 12931-12940.
268. Nettelbeck, D.M.; Miller, D.W.; Jerome, V.; Zuzarte, M.; Watkins, S.J.; Hawkins, R.E.; Muller, R.; Kontermann, R.E. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol. Ther. 2001, 3, 882-891.
269. Miller, C.R.; Buchsbaum, D.J.; Reynolds, P.N.; Douglas, J.T.; Gillespie, G.Y.; Mayo, M.S.; Raben, D.; Curiel, D.T. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 1998, 58, 5738-5748.
270. Nettelbeck, D.M.; Rivera, A.A.; Kupsch, J.; Dieckmann, D.; Douglas, J.T.; Kontermann, R.E.; Alemany, R.; Curiel, D.T. Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. Int. J. Cancer 2004, 108, 136-145.
271. Harvey, T.J.; Burdon, D.; Steele, L.; Ingram, N.; Hall, G.D.; Selby, P.J.; Vile, R.G.; Cooper, P.A.; Shnyder, S.D.; Chester, J.D. Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor. Gene Ther. 2010, 17, 1000-1010.
272. Li, H.J.; Everts, M.; Pereboeva, L.; Komarova, S.; Idan, A.; Curiel, D.T.; Herschman, H.R. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res. 2007, 67, 5354-5361.
273. Chen, C.Y.; May, S.M.; Barry, M.A. Targeting adenoviruses with factor X-single-chain antibody fusion proteins. Hum. Gene Ther. 2010, 21, 739-749.
274. Volpers, C.; Thirion, C.; Biermann, V.; Hussmann, S.; Kewes, H.; Dunant, P.; von der Mark, H.; Herrmann, A.; Kochanek, S.; Lochmuller, H. Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid. J. Virol. 2003, 77, 2093-2104.
275. Hudson, P.J.; Souriau, C. Engineered antibodies. Nat. Med. 2003, 9, 129-134.
276. Kontermann, R.E. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol. Sin. 2005, 26, 1-9.
277. Henning, P.; Andersson, K.M.; Frykholm, K.; Ali, A.; Magnusson, M.K.; Nygren, P.A.; Granio, O.; Hong, S.S.; Boulanger, P.; Lindholm, L. Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. Gene Ther. 2005, 12, 211-224.
278. Pereboeva, L.; Komarova, S.; Roth, J.; Ponnazhagan, S.; Curiel, D.T. Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus. Gene Ther. 2007, 14, 627-637.
279. Watkins, S.J.; Mesyanzhinov, V.V.; Kurochkina, L.P.; Hawkins, R.E. The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. 1997, 4, 1004-1012.
280. Kraaij, R.; van Rijswijk, A.L.; Oomen, M.H.; Haisma, H.J.; Bangma, C.H. Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro. Prostate 2005, 62, 253-259.
281. Korn, T.; Nettelbeck, D.M.; Volkel, T.; Muller, R.; Kontermann, R.E. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J. Gene Med. 2004, 6, 642-651.
282. van Beusechem, V.W.; Mastenbroek, D.C.; van den Doel, P.B.; Lamfers, M.L.; Grill, J.; Wurdinger, T.; Haisma, H.J.; Pinedo, H.M.; Gerritsen, W.R. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Ther. 2003, 10, 1982-1991.
283. van Zeeburg, H.J.; van Beusechem, V.W.; Huizenga, A.; Haisma, H.J.;
284. Miller, W.H.; Brosnan, M.J.; Graham, D.; Nicol, C.G.; Morecroft, I.; Channon, K.M.; Danilov, S. M.; Reynolds, P.N.; Baker, A.H.; Dominiczak, A.F. Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats. Mol. Ther. 2005, 12, 321-327.
285. Reynolds, P.N.; Zinn, K.R.; Gavrilyuk, V.D.; Balyasnikova, I.V.; Rogers, B.E.; Buchsbaum, D.J.; Wang, M.H.; Miletich, D.J.; Grizzle, W.E.; Douglas, J.T.; Danilov, S.M.; Curiel, D.T. A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol. Ther. 2000, 2, 562-578.
286. Reynolds, P.N.; Nicklin, S.A.; Kaliberova, L.; Boatman, B.G.; Grizzle, W.E.; Balyasnikova, I.V.; Baker, A.H.; Danilov, S.M.; Curiel, D.T. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat. Biotechnol. 2001, 19, 838-842.
287. Kashentseva, E.A.; Seki, T.; Curiel, D.T.; Dmitriev, I.P. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res. 2002, 62, 609-616.
288. Dmitriev, I.; Kashentseva, E.; Rogers, B.E.; Krasnykh, V.; Curiel, D.T. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Virol. 2000, 74, 6875-6884.
289. Pereboev, A.V.; Asiedu, C.K.; Kawakami, Y.; Dong, S.S.; Blackwell, J.L.; Kashentseva, E.A.; Triozzi, P.L.; Aldrich, W.A.; Curiel, D.T.; Thomas, J.M.; Dmitriev, I.P. Coxsackievirusadenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Ther. 2002, 9, 1189-1193.
290. Matthews, K.; Noker, P.E.; Tian, B.; Grimes, S.D.; Fulton, R.; Schweikart, K.; Harris, R.; Aurigemma, R.; Wang, M.; Barnes, M.N.; Siegal, G.P.; Hemminki, A.; Zinn, K.; Curiel, D.T.; Alvarez, R.D. Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer. Clin. Cancer Res. 2009, 15, 4131-4137.
291. Cascallo, M.; Alonso, M.M.; Rojas, J.J.; Perez-Gimenez, A.; Fueyo, J.; Alemany, R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol. Ther. 2007, 15, 1607-1615.
292. Rojas, J.J.; Cascallo, M.; Guedan, S.; Gros, A.; Martinez-Quintanilla, J.; Hemminki, A.; Alemany, R. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene Ther. 2009, 16, 1441-1451.
293. Pesonen, S.; Helin, H.; Nokisalmi, P.; Escutenaire, S.; Ribacka, C.; Sarkioja, M.; Cerullo, V.; Guse, K.; Bauerschmitz, G.; Laasonen, L.; Kantola, T.; Ristimaki, A.; Rajecki, M.; Oksanen, M.; Haavisto, E.; Kanerva, A.; Joensuu, T.; Hemminki, A. Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncol. 2010, 49, 117-119.
294. Nokisalmi, P.; Pesonen, S.; Escutenaire, S.; Sarkioja, M.; Raki, M.; Cerullo, V.; Laasonen, L.; Alemany, R.; Rojas, J.; Cascallo, M.; Guse, K.; Rajecki, M.; Kangasniemi, L.; Haavisto, E.; Karioja-Kallio, A.; Hannuksela, P.; Oksanen, M.; Kanerva, A.; Joensuu, T.; Ahtiainen, L.; Hemminki, A. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin. Cancer Res. 2010, 16, 3035-3043.
295. Pesonen, S.; Nokisalmi, P.; Escutenaire, S.; Sarkioja, M.; Raki, M.; Cerullo, V.; Kangasniemi, L.; Laasonen, L.; Ribacka, C.; Guse, K.; Haavisto, E.; Oksanen, M.; Rajecki, M.; Helminen, A.; Ristimaki, A.; Karioja-Kallio, A.; Karli, E.; Kantola, T.; Bauerschmitz, G.; Kanerva, A.; Joensuu, T.; Hemminki, A. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther. 2010, 17, 892-904.
296. Tao, N.; Gao, G.P.; Parr, M.; Johnston, J.; Baradet, T.; Wilson, J.M.; Barsoum, J.; Fawell, S.E. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 2001, 3, 28-35.
297. Worgall, S.; Leopold, P.L.; Wolff, G.; Ferris, B.; Van Roijen, N.; Crystal, R.G. Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum. Gene Ther. 1997, 8, 1675-1684.
298. Jiang, H.; Wang, Z.; Serra, D.; Frank, M.M.; Amalfitano, A. Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol. Ther. 2004, 10, 1140-1142.
299. Parker, A.L.; Waddington, S.N.; Buckley, S.M.; Custers, J.; Havenga, M.J.; van Rooijen, N.; Goudsmit, J.; McVey, J.H.; Nicklin, S.A.; Baker, A.H. Effect of neutralizing sera on factor Xmediated adenovirus serotype 5 gene transfer. J. Virol. 2009, 83, 479-483.
300. Alemany, R.; Curiel, D.T. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 2001, 8, 1347-1353.
301. Fechner, H.; Haack, A.; Wang, H.; Wang, X.; Eizema, K.; Pauschinger, M.; Schoemaker, R.; Veghel, R.; Houtsmuller, A.; Schultheiss, H.P.; Lamers, J.; Poller, W. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 1999, 6, 1520-1535.
302. Leissner, P.; Legrand, V.; Schlesinger, Y.; Hadji, D. A.; van Raaij, M.; Cusack, S.; Pavirani, A.; Mehtali, M. Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther. 2001, 8, 49-57.
303. Martin, K.; Brie, A.; Saulnier, P.; Perricaudet, M.; Yeh, P.; Vigne, E. Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol. Ther. 2003, 8, 485-494.
304. Mizuguchi, H.; Koizumi, N.; Hosono, T.; Ishii-Watabe, A.; Uchida, E.; Utoguchi, N.; Watanabe, Y.; Hayakawa, T. CAR- or alphav integrin-binding ablated adenovirus vectors, but not fibermodified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther. 2002, 9, 769-776.
305. Smith, T.; Idamakanti, N.; Kylefjord, H.; Rollence, M.; King, L.; Kaloss, M.; Kaleko, M.; Stevenson, S.C. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol. Ther. 2002, 5, 770-779.
306. Tamanini, A.; Nicolis, E.; Bonizzato, A.; Bezzerri, V.; Melotti, P.; Assael, B.M.; Cabrini, G. Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells. J. Virol. 2006, 80, 11241-11254.
307. Schoggins, J.W.; Nociari, M.; Philpott, N.; Falck-Pedersen, E. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation. J. Virol. 2005, 79, 11627-11637.
308. Shaw, C.A.; Holland, P.C.; Sinnreich, M.; Allen, C.; Sollerbrant, K.; Karpati, G.; Nalbantoglu, J. Isoform-specific expression of the Coxsackie and adenovirus receptor (CAR) in neuromuscular junction and cardiac intercalated discs. BMC Cell Biol. 2004, 5, 42.
309. Shi, Y.; Chen, C.; Lisewski, U.; Wrackmeyer, U.; Radke, M.; Westermann, D.; Sauter, M.; Tschope, C.; Poller, W.; Klingel, K.; Gotthardt, M. Cardiac deletion of the Coxsackievirusadenovirus receptor abolishes Coxsackievirus B3 infection and prevents myocarditis in vivo. J. Am. Coll. Cardiol. 2009, 53, 1219-1226.
310. Bowles, N.E.; Ni, J.; Kearney, D.L.; Pauschinger, M.; Schultheiss, H.P.; McCarthy, R.; Hare, J.; Bricker, J.T.; Bowles, K.R.; Towbin, J.A. Detection of viruses in myocardial tissues by polymerase chain reaction; evidence of adenovirus as a common cause of myocarditis in children and adults. J. Am. Coll. Cardiol. 2003, 42, 466-472.
311. Excoffon, K.J.; Gansemer, N.D.; Mobily, M.E.; Karp, P.H.; Parekh, K.R.; Zabner, J. Isoformspecific regulation and localization of the coxsackie and adenovirus receptor in human airway epithelia. PLoS One 2010, 5, e9909.
312. Zhang, Y.; Bergelson, J.M. Adenovirus receptors. J. Virol. 2005, 79, 12125-12131.
313. Xia, D.; Henry, L.; Gerard, R.D.; Deisenhofer, J. Structure of the receptor binding domain of adenovirus type 5 fiber protein. Curr. Top. Microbiol. Immunol. 1995, 199 (Pt 1), 39-46.
314. Smith, T.A.; Idamakanti, N.; Marshall-Neff, J.; Rollence, M.L.; Wright, P.; Kaloss, M.; King, L.; Mech, C.; Dinges, L.; Iverson, W.O.; Sherer, A.D.; Markovits, J.E.; Lyons, R.M.; Kaleko, M.; Stevenson, S.C. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum. Gene Ther. 2003, 14, 1595-1604.
315. Lyon, M.; Deakin, J.A.; Mizuno, K.; Nakamura, T.; Gallagher, J.T. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J. Biol. Chem. 1994, 269, 11216-11223.
316. MacArthur, J.M.; Bishop, J.R.; Stanford, K.I.; Wang, L.; Bensadoun, A.; Witztum, J.L.; Esko, J.D. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J. Clin. Invest. 2007, 117, 153-164.
317. Vongchan, P.; Warda, M.; Toyoda, H.; Toida, T.; Marks, R.M.; Linhardt, R.J. Structural characterization of human liver heparan sulfate. Biochim. Biophys. Acta. 2005, 1721, 1-8.
318. Bayo-Puxan, N.; Cascallo, M.; Gros, A.; Huch, M.; Fillat, C.; Alemany, R. Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J. Gen. Virol. 2006, 87, 2487-2495.
319. Smith, T.A.; Idamakanti, N.; Rollence, M.L.; Marshall-Neff, J.; Kim, J.; Mulgrew, K.; Nemerow, G. R.; Kaleko, M.; Stevenson, S.C. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum. Gene Ther. 2003, 14, 777-787.
320. Kritz, A.B.; Nicol, C.G.; Dishart, K.L.; Nelson, R.; Holbeck, S.; Von Seggern, D.J.; Work, L.M.; McVey, J.H.; Nicklin, S.A.; Baker, A.H. Adenovirus 5 fibers mutated at the putative HSPGbinding site show restricted retargeting with targeting peptides in the HI loop. Mol. Ther. 007, 15, 741-749.
321. Di Paolo, N.C.; Kalyuzhniy, O.; Shayakhmetov, D.M. Fiber shaft-chimeric adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivo. J. Virol. 2007, 81, 12249-12259.
322. Wu, E.; Pache, L.; Von Seggern, D.J.; Mullen, T.M.; Mikyas, Y.; Stewart, P.L.; Nemerow, G.R. Flexibility of the adenovirus fiber is required for efficient receptor interaction. J. Virol. 2003, 77, 7225-7235.
323. Terashima, T.; Oka, K.; Kritz, A.B.; Kojima, H.; Baker, A.H.; Chan, L. DRG-targeted helperdependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice. J. Clin. Invest. 2009, 119, 2100-2112.
324. Waddington, S.N.; Parker, A.L.; Havenga, M.; Nicklin, S.A.; Buckley, S.M.; McVey, J.H.; Baker, A.H. Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J. Virol. 2007, 81, 9568-9571.
325. Greig, J.A.; Buckley, S.M.; Waddington, S.N.; Parker, A.L.; Bhella, D.; Pink, R.; Rahim, A.A.; Morita, T.; Nicklin, S.A.; McVey, J.H.; Baker, A.H. Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Mol. Ther. 2009, 17, 1683-1691.
326. Shashkova, E.V.; Doronin, K.; Senac, J.S.; Barry, M.A. Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res. 2008, 68, 5896-5904.
327. Koski, A.; Rajecki, M.; Guse, K.; Kanerva, A.; Ristimaki, A.; Pesonen, S.; Escutenaire, S.; Hemminki, A. Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells. J. Gene Med. 2009, 11, 966-977.
328. Gimenez-Alejandre, M.; Cascallo, M.; Bayo-Puxan, N.; Alemany, R. Coagulation factors determine tumor transduction in vivo. Hum. Gene Ther. 2008, 19, 1415-1419.
329. Shashkova, E.V.; May, S.M.; Doronin, K.; Barry, M.A. Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol. Ther. 2009, 17, 2121-2130.
330. Roberts, D.M.; Nanda, A.; Havenga, M.J.; Abbink, P.; Lynch, D.M.; Ewald, B.A.; Liu, J.; Thorner, A.R.; Swanson, P.E.; Gorgone, D.A.; Lifton, M.A.; Lemckert, A.A.; Holterman, L.; Chen, B.; Dilraj, A.; Carville, A.; Mansfield, K.G.; Goudsmit, J.; Barouch, D.H. Hexonchimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441, 239-243.
331. Roy, S.; Shirley, P.S.; McClelland, A.; Kaleko, M. Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol. 1998, 72, 6875-6879.
332. Gall, J.G.; Crystal, R.G.; Falck-Pedersen, E. Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J. Virol. 1998, 72, 10260-10264.
333. Ostapchuk, P.; Hearing, P. Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E. J. Virol. 2001, 75, 45-51.
334. Wu, H.; Dmitriev, I.; Kashentseva, E.; Seki, T.; Wang, M.; Curiel, D.T. Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J. Virol. 2002, 76, 12775-12782.
335. Youil, R.; Toner, T.J.; Su, Q.; Chen, M.; Tang, A.; Bett, A.J.; Casimiro, D. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum. Gene Ther. 2002, 13, 311-320.
336. Furumoto, K.; Nagayama, S.; Ogawara, K.; Takakura, Y.; Hashida, M.; Higaki, K.; Kimura, T. Hepatic uptake of negatively charged particles in rats: possible involvement of serum proteins in recognition by scavenger receptor. J. Controlled Release 2004, 97, 133-141.
337. Haisma, H.J.; Kamps, J.A.; Kamps, G.K.; Plantinga, J.A.; Rots, M.G.; Bellu, A.R. Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. J. Gen. Virol. 2008, 89, 1097-1105.
338. Chonn, A.; Cullis, P.R.; Devine, D.V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 1991, 146, 4234-4241.
339. Chillon, M.; Lee, J.H.; Fasbender, A.; Welsh, M.J. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther. 1998, 5, 995-1002.
340. De Geest, B.; Snoeys, J.; Van Linthout, S.; Lievens, J.; Collen, D. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Hum. Gene Ther. 2005, 16, 1439-1451.
341. O'Riordan, C.R.; Lachapelle, A.; Delgado, C.; Parkes, V.; Wadsworth, S.C.; Smith, A.E.; Francis, G.E. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 1999, 10, 1349-1358.
342. Corjon, S.; Wortmann, A.; Engler, T.; van Rooijen, N.; Kochanek, S.; Kreppel, F. Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere. Mol. Ther. 2008, 16, 1813-1824.
343. Kreppel, F.; Gackowski, J.; Schmidt, E.; Kochanek, S. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol. Ther. 2005, 12, 107-117.
344. Abuchowski, A.; McCoy, J.R.; Palczuk, N.C.; van Es, T.; Davis, F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 1977, 252, 3582-3586.
345. Abuchowski, A.; Kazo, G.M.; Verhoest, C.R., Jr.; Van Es, T.; Kafkewitz, D.; Nucci, M.L.; Viau, A.T.; Davis, F.F. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984, 7, 175-186.
346. Green, N.K.; Herbert, C.W.; Hale, S.J.; Hale, A.B.; Mautner, V.; Harkins, R.; Hermiston, T.; Ulbrich, K.; Fisher, K.D.; Seymour, L.W. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 2004, 11, 1256-1263.
347. Fasbender, A.; Zabner, J.; Chillon, M.; Moninger, T.O.; Puga, A.P.; Davidson, B.L.; Welsh, M.J. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J. Biol. Chem. 1997, 272, 6479-6489.
348. Croyle, M.A.; Yu, Q.C.; Wilson, J.M. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum. Gene Ther. 2000, 11, 1713-1722.
349. Mok, H.; Palmer, D.J.; Ng, P.; Barry, M.A. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 2005, 11, 66-79.
350. Wortmann, A.; Vohringer, S.; Engler, T.; Corjon, S.; Schirmbeck, R.; Reimann, J.; Kochanek, S.; Kreppel, F. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 2008, 16, 154-162.
351. Hofherr, S.E.; Shashkova, E.V.; Weaver, E.A.; Khare, R.; Barry, M.A. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol. Ther. 2008, 16, 1276-1282.
352. Fisher, K.D.; Stallwood, Y.; Green, N.K.; Ulbrich, K.; Mautner, V.; Seymour, L.W. Polymercoated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001, 8, 341-348.
353. Huang, S.K.; Lee, K.D.; Hong, K.; Friend, D.S.; Papahadjopoulos, D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 1992, 52, 5135-5143.
354. Huang, S.K.; Mayhew, E.; Gilani, S.; Lasic, D.D.; Martin, F.J.; Papahadjopoulos, D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 1992, 52, 6774-6781.
355. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J.W.; Thurston, G.; Roberge, S.; Jain, R.K.; McDonald, D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000, 156, 1363-1380.
356. Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D.A.; Torchilin, V.P.; Jain, R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55, 3752-3756.
357. Romanczuk, H.; Galer, C.E.; Zabner, J.; Barsomian, G.; Wadsworth, S.C.; O'Riordan, C.R. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. Hum. Gene Ther. 1999, 10, 2615-2626.
358. Lanciotti, J.; Song, A.; Doukas, J.; Sosnowski, B.; Pierce, G.; Gregory, R.; Wadsworth, S.; O'Riordan, C. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol. Ther. 2003, 8, 99-107.
359. Gu, D.L.; Gonzalez, A.M.; Printz, M.A.; Doukas, J.; Ying, W.; D'Andrea, M.; Hoganson, D.K.; Curiel, D.T.; Douglas, J.T.; Sosnowski, B.A.; Baird, A.; Aukerman, S.L.; Pierce, G.F. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res. 1999, 59, 2608-2614.
360. Bikfalvi, A.; Sauzeau, C.; Moukadiri, H.; Maclouf, J.; Busso, N.; Bryckaert, M.; Plouet, J.; Tobelem, G. Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects. J. Cell. Physiol. 1991, 149, 50-59.
361. Parker, A.L.; Fisher, K.D.; Oupicky, D.; Read, M.L.; Nicklin, S.A.; Baker, A.H.; Seymour, L.W. Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. J. Drug Targeting 2005, 13, 39-51.
362. Stevenson, M.; Hale, A.B.; Hale, S.J.; Green, N.K.; Black, G.; Fisher, K.D.; Ulbrich, K.; Fabra, A.; Seymour, L.W. Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins. Cancer Gene Ther. 2007, 14, 335-345.
363. Ramos, D.M.; Berston, E.D.; Kramer, R.H. Analysis of integrin receptors for laminin and type IV collagen on metastatic B16 melanoma cells. Cancer Res. 1990, 50, 728-734.
364. Lin, C. S.; Zhang, K.; Kramer, R. Alpha 6 integrin is up-regulated in step increments accompanying neoplastic transformation and tumorigenic conversion of human fibroblasts. Cancer Res. 1993, 53, 2950-2953.
365. Vogelmann, R.; Kreuser, E.D.; Adler, G.; Lutz, M.P. Integrin alpha6beta1 role in metastatic behavior of human pancreatic carcinoma cells. Int. J. Cancer 1999, 80, 791-795.
366. Morrison, J.; Briggs, S.S.; Green, N.; Fisher, K.; Subr, V.; Ulbrich, K.; Kehoe, S.; Seymour, L.W. Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol. Ther. 2008, 16, 244-251.
367. Morrison, J.; Briggs, S.S.; Green, N.K.; Thoma, C.; Fisher, K.D.; Kehoe, S.; Seymour, L.W. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum. Gene Ther. 2009, 20, 239-251.
368. Willemsen, R.A.; Pechar, M.; Carlisle, R.C.; Schooten, E.; Pola, R.; Thompson, A.J.; Seymour, L.W.; Ulbrich, K. Multi-component Polymeric System for Tumour Cell-Specific Gene Delivery Using a Universal Bungarotoxin Linker. Pharm. Res. 2010.
369. Wang, I.J.; Jhuang, M.C.; Chen, Y.H.; Yeh, L.K.; Liu, C.Y.; Young, T.H. Chitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cells. PLoS One 2010, 5, e12085.
370. Harding, S.E. Mucoadhesive interactions. Biochem. Soc. Trans. 2003, 31, 1036-1041.
371. Green, N.K.; Morrison, J.; Hale, S.; Briggs, S.S.; Stevenson, M.; Subr, V.; Ulbrich, K.; Chandler, L.; Mautner, V.; Seymour, L.W.; Fisher, K.D. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J. Gene Med. 2008, 10, 280-289.
372. Pearce, O.M.; Fisher, K.D.; Humphries, J.; Seymour, L.W.; Smith, A.; Davis, B.G. Glycoviruses: chemical glycosylation retargets adenoviral gene transfer. Angew. Chem. Int. Ed. Engl. 2005, 44, 1057-1061.
373. Koizumi, N.; Yamaguchi, T.; Kawabata, K.; Sakurai, F.; Sasaki, T.; Watanabe, Y.; Hayakawa, T.; Mizuguchi, H. Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J. Immunol. 2007, 178, 1767-1773.
374. Walker, G.F.; Fella, C.; Pelisek, J.; Fahrmeir, J.; Boeckle, S.; Ogris, M.; Wagner, E. Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol. Ther. 2005, 11, 418-425.
375. Lichtenstein, D.L.; Spencer, J.F.; Doronin, K.; Patra, D.; Meyer, J.M.; Shashkova, E.V.; Kuppuswamy, M.; Dhar, D.; Thomas, M.A.; Tollefson, A.E.; Zumstein, L.A.; Wold, W.S.; Toth, K. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther. 2009, 16, 644-654.
376. Ying, B.; Toth, K.; Spencer, J.F.; Meyer, J.; Tollefson, A.E.; Patra, D.; Dhar, D.; Shashkova, E.V.; Kuppuswamy, M.; Doronin, K.; Thomas, M.A.; Zumstein, L. A.; Wold, W.S.; Lichtenstein, D. L. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther. 2009, 16, 625-637.
377. Lievens, J.; Snoeys, J.; Vekemans, K.; Van Linthout, S.; de Zanger, R.; Collen, D.; Wisse, E.; De Geest, B. The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer. Gene Ther. 2004, 11, 1523-1531.
378. Wisse, E.; Jacobs, F.; Topal, B.; Frederik, P.; De Geest, B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 2008, 15, 1193-1199.
379. Jacobs, F.; Wisse, E.; De Geest, B. The role of liver sinusoidal cells in hepatocyte-directed gene transfer. Am. J. Pathol. 2010, 176, 14-21.
380. Liang, Z.; Cooper, A.; DeFord, M.E.; Carmeliet, P.; Collen, D.; Castellino, F.J.; Rosen, E.D. Cloning and characterization of a cDNA encoding murine coagulation factor X. Thromb. Haemost. 1998, 80, 87-91.
381. Lenaerts, L.; McVey, J.H.; Baker, A.H.; Denby, L.; Nicklin, S.; Verbeken, E.; Naesens, L. Mouse adenovirus type 1 and human adenovirus type 5 differ in endothelial cell tropism and liver targeting. J. Gene Med. 2009, 11, 119-127.
382. Falanga, A. Thrombophilia in cancer. Semin. Thromb. Hemost. 2005, 31, 104-110.
383. Ferrigno, D.; Buccheri, G.; Ricca, I. Prognostic significance of blood coagulation tests in lung cancer. Eur. Respir. J. 2001, 17, 667-673.
384. Iversen, N.; Lindahl, A.K.; Abildgaard, U. Elevated plasma levels of the factor Xa-TFPI complex in cancer patients. Thromb. Res. 2002, 105, 33-36.
385. Atencio, I.A.; Grace, M.; Bordens, R.; Fritz, M.; Horowitz, J.A.; Hutchins, B.; Indelicato, S.; Jacobs, S.; Kolz, K.; Maneval, D.; Musco, M.L.; Shinoda, J.; Venook, A.; Wen, S.; Warren, R. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial. Cancer Gene Ther. 2006, 13, 169-181.
386. Reid, T.; Galanis, E.; Abbruzzese, J.; Sze, D.; Wein, L.M.; Andrews, J.; Randlev, B.; Heise, C.; Uprichard, M.; Hatfield, M.; Rome, L.; Rubin, J.; Kirn, D. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002, 62, 6070-6079.
387. Reid, T.; Warren, R.; Kirn, D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 2002, 9, 979-986.
388. Raper, S.E.; Yudkoff, M.; Chirmule, N.; Gao, G.P.; Nunes, F.; Haskal, Z.J.; Furth, E.E.; Propert, K.J.; Robinson, M.B.; Magosin, S.; Simoes, H.; Speicher, L.; Hughes, J.; Tazelaar, J.; Wivel, N.A.; Wilson, J.M.; Batshaw, M.L. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther. 2002, 13, 163-175.
389. Di Paolo, N.C.; Miao, E.A.; Iwakura, Y.; Murali-Krishna, K.; Aderem, A.; Flavell, R.A.; Papayannopoulou, T.; Shayakhmetov, D.M. Virus Binding to a Plasma Membrane Receptor Triggers Interleukin-1alpha-Mediated Proinflammatory Macrophage Response. Immunity 2009, 31, 110-121.